We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+36.88%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$221M
AUM Growth
+$32.8M
Cap. Flow
-$14M
Cap. Flow %
-6.32%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
–
Reduced
5
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$5.7M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$4.03M
3
INSM icon
Insmed
INSM
+$1.25M
4
NTRA icon
Natera
NTRA
+$964K
5
XLRN
Acceleron Pharma
XLRN
+$922K

Sector Composition

Rank Sector Weight
1 Healthcare 36.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$79.5M 35.87%
1,672,714
– –
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$60.9M 27.51%
2,726,568
-242,081
-8% -$5.7M
INSM icon
3
Insmed
INSM
$23.1B
$26.7M 12.07%
919,436
-48,200
-5% -$1.25M
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$21.7M 9.78%
1,586,220
– –
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$18.4M 8.33%
1,488,444
-69,420
-4% -$776K
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$8.78M 3.97%
188,602
-21,000
-10% -$922K
BDSI
7
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.8M 1.72%
717,133
-79,600
-10% -$364K
TWST icon
8
Twist Bioscience
TWST
$5.39B
$1.69M 0.76%
72,849
– –
ADAP
9
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-700,000
Closed -$4.03M
NTRA icon
10
Natera
NTRA
$37.3B
– –
-69,045
Closed -$964K

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q1 2019 Portfolio in Review

As of Q1 2019, Foresite Capital Management II held 10 positions worth $221M, up 17% from $189M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II withdrew a net $14M in Q1 2019, closing 2 positions and reducing 5 holdings. Its most notable exit was Adaptimmune Therapeutics, an estimated $4.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, up from 30% a quarter earlier.

  • Foresite Capital Management II's biggest Q1 2019 reduction was Aimmune Therapeutics, cutting an estimated $5.7M.
  • Foresite Capital Management II fully exited Adaptimmune Therapeutics in Q1 2019, selling an estimated $4.03M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $221M portfolio in Q1 2019.
  • Foresite Capital Management II opened 0 new positions and closed 2 in Q1 2019.
  • Foresite Capital Management II's portfolio value rose 17% quarter-over-quarter to $221M.

Based on Foresite Capital Management II's 13F filing for Q1 2019, filed 14 May 2019.